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Abstract
Migraine is a debilitating neurological disorder affecting around 1 in 7 people worldwide, but its 
molecular mechanisms remain poorly understood. Some debate exists over whether migraine is a 
disease of vascular dysfunction or a result of neuronal dysfunction with secondary vascular 
changes. Genome-wide association (GWA) studies have thus far identified 13 independent loci 
associated with migraine. To identify new susceptibility loci, we performed the largest genetic 
study of migraine to date, comprising 59,674 cases and 316,078 controls from 22 GWA studies. 
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We identified 44 independent single nucleotide polymorphisms (SNPs) significantly associated 
with migraine risk (P < 5 × 10−8) that map to 38 distinct genomic loci, including 28 loci not 
previously reported and the first locus identified on chromosome X. In subsequent computational 
analyses, the identified loci showed enrichment for genes expressed in vascular and smooth 
muscle tissues, consistent with a predominant theory of migraine that highlights vascular 
etiologies.
Migraine is ranked as the third most common disease worldwide, with a lifetime prevalence 
of 15–20%, affecting up to one billion people across the globe1,2. It ranks as the 7th most 
disabling of all diseases worldwide (or 1st most disabling neurological disease) in terms of 
years of life lost to disability1 and is the 3rd most costly neurological disorder after dementia 
and stroke3. There is debate about whether migraine is a disease of vascular dysfunction, or 
a result of neuronal dysfunction with vascular changes representing downstream effects not 
themselves causative of migraine4,5. However, genetic evidence favoring one theory versus 
the other is lacking. At the phenotypic level, migraine is defined by diagnostic criteria from 
the International Headache Society6. There are two prevalent sub-forms: migraine without 
aura is characterized by recurrent attacks of moderate or severe headache associated with 
nausea or hypersensitivity to light and sound. Migraine with aura is characterized by 
transient visual, sensory, or speech symptoms usually followed by a headache phase similar 
to migraine without aura.
Family and twin studies estimate a heritability of 42% (95% confidence interval [CI] = 36–
47%) for migraine7, pointing to a genetic component of the disease. Despite this, genetic 
association studies have revealed relatively little about the molecular mechanisms that 
contribute to pathophysiology. Understanding has been limited partly because, to date, only 
13 genome-wide significant risk loci have been identified for the prevalent forms of 
migraine8–11. In familial hemiplegic migraine (FHM), a rare Mendelian form of the disease, 
three ion transport-related genes (CACNA1A, ATP1A2 and SCN1A) have been 
implicated12–14. These findings suggest that mechanisms that regulate neuronal ion 
homeostasis might also be involved in migraine more generally, however, no genes related to 
ion transport have yet been identified for these more prevalent forms of migraine15.
We performed a meta-analysis of 22 genome-wide association (GWA) studies, consisting of 
59,674 cases and 316,078 controls collected from six tertiary headache clinics and 27 
population-based cohorts through our worldwide collaboration in the International Headache 
Genetics Consortium (IHGC). This combined dataset contained over 35,000 new migraine 
cases not included in previously published GWA studies. Here we present the findings of 
this new meta-analysis, including 38 genomic loci, harboring 44 independent association 
signals identified at levels of genome-wide significance, which support current theories of 
migraine pathophysiology and also offer new insights into the disease.
Gormley et al. Page 2
Nat Genet. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
RESULTS
Significant associations at 38 independent genomic loci
The primary meta-analysis was performed on all migraine samples available through the 
IHGC, regardless of ascertainment. These case samples included both individuals diagnosed 
by a doctor as well as individuals with self-reported migraine via questionnaires. Study 
design and sample ascertainment for each individual study is outlined in the Supplementary 
Note (and summarized in Supplementary Table 1). The final combined sample consisted of 
59,674 cases and 316,078 controls in 22 non-overlapping case-control datasets (Table 1). All 
samples were of European ancestry. Before including the largest study from 23andMe, we 
confirmed that it did not contribute any additional heterogeneity compared to the other 
population and clinic-based studies (Supplementary Table 2).
The 22 individual GWA studies completed standard quality control protocols (Online 
Methods) summarized in Supplementary Table 3. Missing genotypes were then imputed 
into each sample using a common 1000 Genomes Project reference panel16. Association 
analyses were performed within each study using logistic regression on the imputed marker 
dosages while adjusting for sex and other covariates where necessary (Online Methods and 
Supplementary Table 4). The association results were combined using an inverse-variance 
weighted fixed-effects meta-analysis. Markers were filtered for imputation quality and other 
metrics (Online Methods) leaving 8,094,889 variants for consideration in our primary 
analysis.
Among these variants in the primary analysis, we identified 44 genome-wide significant 
SNP associations (P < 5 × 10−8, Supplementary Figure 1) that are independent (r2 < 0.1) 
with regards to linkage disequilibrium (LD). We validated the 44 SNPs by comparing 
genotypes in a subset of the sample to those obtained from whole-genome sequencing 
(Supplementary Table 5). To help identify candidate risk genes from these, we defined an 
associated locus as the genomic region bounded by all markers in LD (r2 > 0.6 in 1000 
Genomes, Phase I, EUR individuals) with each of the 44 index SNPs and in addition, all 
such regions in close proximity (< 250 kb) were merged. From these defined regions we 
implicate 38 genomic loci for the prevalent forms of migraine, 28 of which have not 
previously been reported (Figure 1).
These 38 loci replicate 10 of the 13 previously reported genome-wide associations to 
migraine and six loci contain a secondary genome-wide significant SNP not in LD (r2 < 0.1) 
with the top SNP in the locus (Table 2). Five of these secondary signals were found in 
known loci (at LRP1/STAT6/SDR9C7, PRDM16, FHL5/UFL1, TRPM8/HJURP, and near 
TSPAN2/NGF), while the sixth was found within one of the 28 new loci (PLCE1). 
Therefore, out of the 44 independent SNPs reported here, 34 represent new associations to 
migraine. Three previously reported loci that were associated to subtypes of migraine 
(rs1835740 near MTDH for migraine with aura, rs10915437 near AJAP1 for migraine 
clinical-samples, and rs10504861 near MMP16 for migraine without aura)8,11 show only 
nominal significance in the current meta-analysis (P = 5 × 10−3 for rs1835740, P = 4.4 × 
10−5 for rs10915437, and P = 4.9 × 10−5 for rs10504861, Supplementary Table 6), however, 
these loci have since been shown to be associated to specific phenotypic features of 
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migraine17 and therefore may require a more phenotypically homogeneous sample to be 
accurately assessed for association. Four out of 44 SNPs (at TRPM8/HJURP, near 
ZCCHC14, MRVI1, and near CCM2L/HCK) exhibited moderate heterogeneity across the 
individual GWA studies (Cochran’s Q P-value < 0.05, Supplementary Table 7) therefore at 
these markers we applied a random effects model18.
Characterization of the associated loci
In total, 32 of 38 (84%) loci overlap with transcripts from protein-coding genes, and 17 
(45%) of these regions contain just a single gene (see Supplementary Figure 2 for regional 
association plots and Supplementary Table 8 for additional locus information). Among the 
38 loci, only two contain ion channel genes (KCNK519 and TRPM820). Hence, despite 
previous hypotheses of migraine as a potential channelopathy5,21, the loci identified to date 
do not support common variants in ion channel genes as strong susceptibility components in 
prevalent forms of migraine. However, three other loci do contain genes involved more 
generally in ion homeostasis (SLC24A322, ITPK123, and GJA124, Supplementary Table 9).
Several of the genes have previous associations to vascular disease (PHACTR1,25,26 
TGFBR2,27 LRP1,28 PRDM16,29 RNF213,30 JAG1,31 HEY2,32 GJA133, ARMS234), or are 
involved in smooth muscle contractility and regulation of vascular tone (MRVI1,35 GJA1,36 
SLC24A3,37 NRP138). Three of the 44 migraine index SNPs have previously reported 
associations in the National Human Genome Research Institute (NHGRI) GWAS catalog at 
exactly the same SNP (rs9349379 at PHACTR1 with coronary heart disease39–41, coronary 
artery calcification42, and cervical artery dissection26; rs11624776 near ITPK1 with thyroid 
hormone levels43; and rs11172113 at LRP1/STAT6/SDR9C7 with pulmonary function44; 
Supplementary Table 10). Six of the loci harbor genes that are involved in nitric oxide 
signaling and oxidative stress (REST45, GJA146, YAP147, PRDM1648, LRP149, and 
MRVI150).
From each locus we chose the nearest gene to the index SNP to assess gene expression 
activity in tissues from the GTEx consortium (Supplementary Figure 3). While we found 
that most of the putative migraine loci genes were expressed in many different tissue types, 
we could detect tissue specificity in certain instances whereby some genes showed 
significantly higher expression in a particular tissue group relative to the others. For instance 
four genes were more actively expressed in brain (GPR149, CFDP1, DOCK4, and 
MPPED2) compared to other tissues, whereas eight genes were specifically active in 
vascular tissues (PRDM16, MEF2D, FHL5, C7orf10, YAP1, LRP1, ZCCHC14, and JAG1). 
Many other putative migraine loci genes were actively expressed in more than one tissue 
group.
Genomic inflation and LD-score regression analysis
To assess whether the 38 loci harbor true associations with migraine rather than reflecting 
systematic differences between cases and controls (such as population stratification) we 
analyzed the genome-wide inflation of test statistics in our primary meta-analysis. As 
expected for a complex polygenic trait, the distribution of test statistics deviates from the 
null (genomic inflation factor λGC = 1.24, Supplementary Figure 4) which is in line with 
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other large GWA study meta-analyses51–54. Since much of the inflation in a polygenic trait 
arises from LD between the causal SNPs and many other neighboring SNPs in the local 
region, we LD-pruned the data to create a set of LD-independent markers (i.e. in PLINK55 
with a 250-kb sliding window and r2 > 0.2). The resulting genomic inflation was reduced 
(λGC = 1.15, Supplementary Figure 5) and likely reflects the inflation remaining due to the 
polygenic signal at many independent loci, including those not yet significantly associated.
To confirm that the observed inflation is primarily coming from true polygenic signal, we 
analyzed the data from all imputed markers using LD-score regression56. This method tests 
for a linear relationship between marker test statistics and LD score, defined as the sum of r2 
values between a marker and all other markers within a 1-Mb window. The primary analysis 
results show a linear relationship between association test statistics and LD-score 
(Supplementary Figure 6) and estimate that the majority (88.2%) of the inflation in test 
statistics can be ascribed to true polygenic signal rather than population stratification or 
other confounders. These results are consistent with the theory of polygenic disease 
architecture shown previously by both simulation and real data for GWAS samples of similar 
size57.
Migraine subtype analyses
To elucidate pathophysiological mechanisms underpinning the migraine aura, we performed 
a secondary analysis by creating two subsets that included only samples with the subtypes; 
migraine with aura and migraine without aura. These subsets only included those studies 
where sufficient information was available to assign a diagnosis of either subtype according 
to classification criteria standardized by the International Headache Society (IHS)6. For the 
population-based studies this involved questionnaires, whereas for the clinic-based studies 
the diagnosis was assigned on the basis of a structured interview by telephone or in person. 
A stricter diagnosis is required for the subtypes as migraine aura is often challenging to 
distinguish from other neurological features that can present as symptoms from unrelated 
conditions.
As a result, the migraine subtype analyses consisted of considerably smaller sample sizes 
compared to the main analysis (6,332 cases vs. 144,883 controls for migraine with aura and 
8,348 cases vs. 139,622 controls for migraine without aura, Table 1). As with the primary 
analysis, the test statistics for migraine with aura or migraine without aura were consistent 
with underlying polygenic architecture rather than other potential sources of inflation 
(Supplementary Figure 7–Supplementary Figure 8). For the migraine without aura subset 
analysis we found seven significantly associated genomic loci (near TSPAN2, TRPM8, 
PHACTR1, FHL5, ASTN2, near FGF6, and LRP1, Supplementary Table 11 and 
Supplementary Figure 9). All seven of these loci were already identified in the primary 
analysis, possibly reflecting the fact that migraine without aura is the most common form of 
migraine (around 2 in 3 cases) and likely drives these association signals in the primary 
analysis. Notably, no loci were associated to migraine with aura in the other subset analysis 
(Supplementary Figure 10).
To investigate whether excess heterogeneity could be contributing to the lack of associations 
in migraine with aura, we performed a heterogeneity analysis between the two subgroups 
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(Online Methods and Supplementary Table 12). We selected the 44 LD-independent SNPs 
associated from the primary analysis and used a random-effects model to combine the 
migraine with aura and migraine without aura samples in a meta-analysis that allows for 
heterogeneity between the two migraine groups58. We found little heterogeneity with only 
seven of the 44 loci (at MEF2D, PHACTR1, near REST/SPINK2, ASTN2, PLCE1, 
MPPED2, and near MED14/USP9X) exhibiting signs of heterogeneity across subtype 
groups (Supplementary Table 13).
Credible sets of markers within each locus
For each of the 38 migraine-associated loci, we defined a credible set of markers that could 
plausibly be considered as causal using a Bayesian-likelihood based approach59. This 
method incorporates evidence from association test statistics and the LD structure between 
SNPs in a locus (Online Methods). A list of the credible set SNPs obtained for each locus is 
provided in Supplementary Table 14. We found three instances (in RNF213, PLCE1, and 
MRVI1) where the association signal could be credibly attributed to exonic missense 
polymorphisms (Supplementary Table 15). However, most of the credible markers at each 
locus were either intronic or intergenic, which is consistent with the theory that most 
variants detected by GWA studies involve regulatory effects on gene expression rather than 
disrupting protein structure60,61.
Overlap with eQTLs in specific tissues
To identify migraine loci that might influence gene expression, we used previously 
published datasets that catalog expression quantitative trait loci (eQTLs) in either of two 
microarray-based studies from peripheral venous blood (N1 = 3,754) or from human brain 
cortex (N2 = 550). Additionally, we used a third study based on RNAseq data from a 
collection of 42 tissues and three cell lines (N3 = 1,641) from the Genotype-Tissue 
Expression (GTEx) consortium62. While this data has the advantage of a diverse tissue 
catalog, the number of samples per tissue is relatively small (Supplementary Table 16) 
compared to the two microarray datasets, possibly resulting in reduced power to detect 
significant eQTLs in some tissues. Using these datasets we applied a method based on the 
overlap of migraine and eQTL credible sets to identify eQTLs that could explain 
associations at the 38 migraine loci (Online Methods). This approach merged the migraine 
credible sets defined above with credible sets from cis-eQTL signals within a 1-Mb window 
and tested if the association signals between the migraine and eQTL credible sets were 
correlated. After adjusting for multiple testing we found no plausible eQTL associations in 
the peripheral blood or brain cortex data (Supplementary Tables 17–18 and Supplementary 
Figure 11). In GTEx, however, we found evidence for overlap from eQTLs in three tissues 
(Lung, Tibial Artery, and Aorta) at the HPSE2 locus and in one tissue (Thyroid) at the 
HEY2/NCOA7 locus (Supplementary Table 19 and Supplementary Figure 12).
In summary, from three datasets we implicate eQTL signals at only two loci (HPSE2 and 
HEY2). This low number (two out of 38) is consistent with previous studies which have 
observed that available eQTL catalogues currently lack sufficient tissue specificity and 
developmental diversity to provide enough power to provide meaningful biological insight53. 
No plausibly causal eQTLs were observed in expression data from brain.
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Gene expression enrichment in specific tissues
To understand if the 38 migraine loci as a group are enriched for expression in certain tissue 
types, we again used the GTEx pilot data62 (see Online Methods). We found four tissues 
that were significantly enriched (after Bonferroni correction) for expression of the migraine 
genes (Figure 2). The two most strongly enriched tissues were part of the cardiovascular 
system; the aorta and tibial artery. Two other significant tissues were from the digestive 
system; esophagus muscularis and esophageal mucosa. We replicated these enrichment 
results using the DEPICT63 tool and an independent microarray-based gene expression 
dataset (Online Methods). DEPICT highlighted four tissues (Figure 3 and Supplementary 
Table 20) with significant enrichment of genes within the migraine loci; arteries (P = 1.58 × 
10−5), the upper gastrointestinal tract (P = 2.97 × 10−3), myometrium (P = 3.03 × 10−3), and 
stomach (P = 3.38 × 10−3).
Taken together, the expression analyses implicate arterial and gastrointestinal (GI) tissues. 
To discover if this enrichment signature could be attributed to a more specific type of 
smooth muscle, we examined the expression of the nearest genes at migraine loci in a panel 
of 60 types of human smooth muscle tissue64. Overall, migraine loci genes were not 
significantly enriched in a particular class of smooth muscle (Supplementary Figures 13–
15). This suggests that the enrichment of migraine risk variants in genes expressed in tissues 
with a smooth muscle component is not specific to blood vessels, the stomach or GI tract, 
but rather appears to be generalizable across vascular and visceral smooth muscle types.
Combined, these enrichment results suggest that some of the genes affected by migraine-
associated variants are highly expressed in vascular tissues and their dysfunction could play 
a role in migraine. Furthermore, the results suggest that other tissue types (e.g. smooth 
muscle) could also play a role and this may become evident once more migraine loci are 
discovered.
Enrichment in tissue-specific enhancers
To further assess the hypothesis that migraine variants might operate via effects on gene-
regulation, we investigated the degree of overlap with histone modifications. Using 
candidate causal variants from the migraine loci, we examined their enrichment within cell-
type specific enhancers from 56 primary human tissues and cell types from the Roadmap 
Epigenomics65 and ENCODE projects66 (Online Methods and Supplementary Table 21). 
These variants showed highest enrichment in tissues from the mid-frontal lobe and 
duodenum smooth muscle but were not significant after adjusting for multiple testing 
(Figure 4).
Gene set enrichment analyses
To implicate underlying biological pathways involved in migraine, we applied a Gene 
Ontology (GO) over-representation analysis of the 38 migraine loci (Online Methods). We 
found nine vascular-related biological function categories that were significantly enriched 
after correction for multiple testing (Supplementary Table 22). Interestingly, we found little 
statistical support from the identified loci for some molecular processes that have been 
previously linked to migraine, e.g. ion homeostasis, glutamate signaling, serotonin signaling, 
Gormley et al. Page 7
Nat Genet. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
nitric oxide signaling, and oxidative stress. However, it is possible that the lack of 
enrichment for these functions may be explained by recognizing that current annotations for 
many genes and pathways are far from comprehensive, or that larger numbers of migraine 
loci need to be identified before we have sensitivity to detect enrichment in these 
mechanisms.
For a more comprehensive pathway analysis we used DEPICT, which incorporates gene co-
expression information from microarray data to implicate additional, functionally less well-
characterized genes in known biological pathways, protein-protein complexes and mouse 
phenotypes63 (by forming so-called ‘reconstituted gene sets’). From DEPICT we identified 
67 reconstituted gene sets that are significantly enriched (FDR < 5%) for genes found 
among the migraine associated loci (Supplementary Table 23). Because the reconstituted 
gene sets had genes in common, we clustered them into 10 distinct groups (Figure 5 and 
Online Methods). Several gene sets, including the most significantly enriched reconstituted 
gene set (Abnormal Vascular Wound Healing; P = 1.86 × 10−6), were grouped into clusters 
related to cell-cell interactions (ITGB1 PPI, Adherens Junction, and Integrin Complex). 
Several of the other gene set clusters were also related to vascular-biology (Figure 5 and 
Supplementary Table 23). We still did not observe any support for molecular processes with 
hypothesized links to migraine (Supplementary Table 24), however, this could again be due 
to the reasons outlined above.
DISCUSSION
In what is the largest genetic study of migraine to date, we identified 38 distinct genomic 
loci harboring 44 independent susceptibility markers for the prevalent forms of migraine. We 
provide evidence that migraine-associated genes are involved both in arterial and smooth 
muscle function. Two separate analyses, the DEPICT and the GTEx gene expression 
enrichment analyses, point to vascular and smooth muscle tissues being involved in common 
variant susceptibility to migraine. The vascular finding is consistent with known co-
morbidities and previously reported shared polygenic risk between migraine, stroke and 
cardiovascular diseases67,68. Furthermore, a recent GWA study of Cervical Artery 
Dissection (CeAD) identified a genome-wide significant association at the same index SNP 
(rs9349379 in the PHACTR1 locus) as is associated to migraine, suggesting the possibility 
of partially shared genetic components between migraine and CeAD26. These results suggest 
that vascular dysfunction and possibly also other smooth muscle dysfunction likely play 
roles in migraine pathogenesis.
The support for vascular and smooth muscle enrichment of the loci is strong, with multiple 
lines of evidence from independent methods and independent datasets. However, it remains 
likely that neurogenic mechanisms are also involved in migraine. For example, several lines 
of evidence from previous studies have pointed to such mechanisms5,69–72. We found some 
support for this when looking at gene expression of individual genes at the 38 loci 
(Supplementary Figure 3 and Supplementary Table 25), where several genes were 
specifically active in brain tissues. While we did not observe statistically significant 
enrichment in brain across all loci, it may be that more associated loci are needed to detect 
this. Alternatively, it could be due to difficulties in collecting appropriate brain tissue 
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samples with enough specificity, or other technical challenges. Additionally, there is less 
clarity of the biological mechanisms for a neurological disease like migraine compared to 
some other common diseases, e.g. autoimmune or cardio-metabolic diseases where 
intermediate risk factors and underlying mechanisms are better understood.
Interestingly, some of the analyses highlight gastrointestinal tissues. Although migraine 
attacks may include gastrointestinal symptoms (e.g. nausea, vomiting, diarrhea)6 it is likely 
that the signals observed here broadly represent smooth muscle signals rather than 
gastrointestinal specificity. Smooth muscle is a predominant tissue of the intestine, yet 
specific smooth muscle subtypes were not available to test this hypothesis in our primary 
enrichment analyses. We showed instead in a range of 60 smooth muscle subtypes, that the 
migraine loci are expressed in many types of smooth muscle, including vascular 
(Supplementary Figures 14–15). These results, while not conclusive, suggest that the 
enrichment of the migraine loci in smooth muscle is not specific to the stomach and GI tract.
Our results implicate cellular pathways and provide an opportunity to determine whether the 
genomic data supports previously presented hypotheses of mechanisms linked to migraine. 
One prevailing hypothesis, stimulated by findings in familial hemiplegic migraine (FHM), 
has been that migraine is a channelopathy5,21. Among the 38 migraine loci, only two harbor 
known ion channels (KCNK519 and TRPM820), while three additional loci (SLC24A322, 
near ITPK123, and near GJA124) can be linked to ion homeostasis. This further supports the 
findings of previous studies that in common forms of migraine, ion channel dysfunction is 
not the major pathophysiological mechanism15. However, more generally, genes involved in 
ion homeostasis could be a component of the genetic susceptibility. Moreover, we cannot 
exclude that ion channels could still be important contributors in migraine with aura, the 
form most closely resembling FHM, as our ability to identify loci in this subgroup is more 
challenging. Another suggested hypothesis relates to oxidative stress and nitric oxide (NO) 
signaling73–75. Six genes with known links to oxidative stress and NO were identified within 
these 38 loci (REST45, GJA146, YAP147, PRDM1648, LRP149, and MRVI150). This is in 
line with previous findings11, however, the DEPICT pathway analysis observed no 
association between NO-related reconstituted gene sets and migraine (FDR > 0.54, 
Supplementary Table 24).
Notably, in the migraine subtype analyses, it was possible to identify specific loci for 
migraine without aura but not for migraine with aura. However, the heterogeneity analysis 
(Supplementary Tables 12–13) demonstrated that most of the identified loci are implicated 
in both migraine subtypes. This suggests that the absence of significant loci in the migraine 
with aura analysis is mainly due to lack of power from the reduced sample size. 
Additionally, as shown by the LD score analysis (Supplementary Figures 6–8), the amount 
of heritability captured by the migraine with aura dataset is considerably lower than 
migraine without aura, such that in order to reach comparable power, a sample size of two- 
to three-times larger would be required. This may reflect a higher degree of heterogeneity in 
the clinical capture, more complex underlying biology, or even a larger contribution to risk 
from low-frequency and rare variation for this form of the disease.
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In conclusion, the 38 genomic loci identified in this study support the notion that factors in 
vascular and smooth muscle tissues contribute to migraine pathophysiology and that the two 
major subtypes of migraine, migraine with aura and migraine without aura, have a partially 
shared underlying genetic susceptibility profile.
ONLINE METHODS
Study design and phenotyping
A description of the study design, ascertainment and phenotyping for each GWA study is 
provided in the Supplementary Note.
Quality Control
The 22 individual GWA studies were subjected to pre-established quality control (QC) 
protocols as recommended elsewhere76,77. Differences in genotyping chips, DNA quality 
and calling pipelines necessitated that QC parameters were tuned separately for each study. 
At a minimum, we excluded markers with high missingness rates (>5%), low minor allele 
frequency (<1%), and failing a test of Hardy-Weinberg equilibrium. We also excluded 
individuals with a high proportion of missing genotypes (>5%) and used identity-by-descent 
(IBD) estimates to remove related individuals (IBD > 0.185). A summary of the genotyping 
platforms, QC, and software used in each study is provided in Supplementary Table 3. To 
control for population stratification within each study, we merged the genotypes passing QC 
filters with HapMap III data from three populations; European (CEU), Asian (CHB+JPT) 
and African (YRI). We then performed a principal components analysis on the merged 
dataset and excluded any (non-European) population outliers. To control for any sub-
European population structure, we performed a second principal components analysis within 
each study to ensure that cases and controls were clustering together. Any principal 
components that were significantly associated with the phenotype were included as 
covariates in the model when calculating test statistics for the meta-analysis (Supplementary 
Table 4).
Imputation
Following study-level QC, estimated haplotypes were phased for each individual using (in 
most instances) the program SHAPEIT78. Missing genotypes were then imputed into these 
haplotypes using the program IMPUTE279 and a mixed-population 1000 Genomes Project16 
reference panel (March 2012, phase I, v3 release or later). A minority of contributing studies 
used alternative programs for phasing and imputation; BEAGLE80, MACH81, MINIMAC82, 
or in-house custom software. A summary of software and procedures used is provided in 
Supplementary Table 3.
Statistical analysis
Individual study association analyses were implemented using logistic regression with an 
additive model on the imputed dosage of the effect allele. All models were adjusted for sex 
and other relevant covariates when appropriate (Supplementary Table 4). As age information 
was not available for individuals from all studies we were not able to adjust for it in our 
models. However, we note that all of the GWA studies were comprised of adults past the 
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typical age of onset, hence, age is at most a non-confounding factor and false positive rates 
would not be affected by its inclusion/exclusion. The programs used for performing the 
within-study association analyses were either SNPTEST, PLINK or R (URLs). The program 
GWAMA was then used to perform a fixed-effects meta-analysis weighted by the inverse 
variances to obtain a combined effect size, standard error and P-value at each marker. We 
excluded markers in any study that had low imputation quality scores (IMPUTE2 INFO < 
0.6 or MACH r2 < 0.6) or low minor allele frequency (MAF < 0.01). Additionally, we 
filtered out markers that were missing from more than half of all studies (12 or more) or 
exhibited high heterogeneity (heterogeneity index i2 > 0.75). After filtering, 8,045,569 total 
markers were tested in the meta-analysis.
Chromosome X meta-analysis
Due to the different ploidy of males and females on chromosome X, we implemented a 
model of X-chromosome inactivation (XCI) that assumes an equal effect of alleles in both 
males and females. This was achieved by scaling male dosages to the range 0–2 to match 
that of females. In total, 57,756 cases and 299,109 controls were available for the X-
chromosome analysis (Supplementary Table 1). The reduced sample size compared to the 
autosomal data occurred because some of the individual GWA studies (EGCUT, Rotterdam 
III, Twins UK, and 846 controls from GSK for the ‘German MO’ study) did not contribute 
chromosome X data.
LD score regression analysis
We conducted a univariate heritability analysis based on summary statistics using LD score 
regression (LDSC) v1.0.056. For this analysis, high-quality common SNPs were extracted 
from the summary statistics by filtering the data on the following criteria: presence among 
the HapMap Project Phase 3 SNPs83, allele matching to 1000 Genomes data, no strand 
ambiguity, INFO score > 0.9, MAF >= 1%, and missingness less than two thirds of the 90th 
percentile of the total sample size. The HLA region (chromosome 6, 25–35 Mb) was 
excluded from the analysis. From this data, we used LDSC to quantify the proportion of the 
total inflation in chi-square statistics that can be ascribed to polygenic heritability by 
calculating the ratio of the LDSC intercept estimate and the chi-square mean using the 
formula described in the original publication56.
Heterogeneity analysis of migraine subtypes
To determine if heterogeneity between the migraine subtypes might have affected our ability 
to identify new loci, we performed an additional meta-analysis using a subtype-
differentiated approach that allows for different allelic effects between two groups58. Since a 
large proportion of the controls were shared in the original migraine with aura and migraine 
without aura datasets (Table 1), for this analysis we created two additional subsets of the 
migraine subtype data that contained no overlapping controls between the two new subsets 
(Supplementary Table 12). The new migraine with aura subset consisted of 4,837 cases and 
49,174 controls and the new migraine without aura subset consisted of 4,833 cases and 
106,834 controls. To assess the heterogeneity observed, we chose the 44 index SNPs from 
the primary meta-analysis and applied the subtype-differentiated meta-analysis method to 
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these. We observed that only seven out of the 44 SNPs exhibited heterogeneity in the 
subtype-differentiated test (Heterogeneity P-value < 0.05, Supplementary Table 13) 
suggesting that most loci likely affect risk for both subtypes.
Defining credible sets
Within each migraine-associated locus, we defined a credible set of variants that could be 
considered 99% likely to contain a causal variant. The method has been introduced in detail 
elsewhere53,59 and is outlined again briefly here. Assume D is the data including the 
genotype matrix X for all of the P variants (genotype for variant j is denoted as xj) and 
disease status Y (for N individuals), and β is the model parameters. We define the ‘model’, 
denoted A, as the causal status for all of the P variants in the locus: A = {aj}, in which aj is 
the causal status for variant j. aj = 1 if the variant j is causal, whereas aj = 0 if it is not. We 
assume that there is one and only one genuine signal for each locus, therefore, one and only 
one of the P variants is causal: Σj aj = 1. For convenience, we define Aj as the model that 
only variant j is causal, and A0 as the model that no variant is causal (null model). The 
probability for model Aj(where variant j is the only causal variant in this locus) given the 
data can be calculated using Bayes’ rule:
(1)
We estimate Equation (1) using the steepest descent approach84. Making the assumption of a 
flat prior on the model parameters, we approximate the integral over the model parameters 
using their maximum likelihood estimator (β̂j):
(2)
where the sample size is denoted by N and the number of fitted parameters for model Aj is 
denoted by |βj|· |βj| is a constant because model Aj has the same number of parameters 
across all variants. In the framework of a generalized linear model, the deviance for two 
nested models follows an approximate chi-square distribution. We therefore define χj2 as the 
deviance comparing the null model and the model in which variant j is causal
(3)
We further show that χj2 can be calculated as the chi-square statistic of fitting a binomial 
model with the disease status (Y) as the dependent variable and the genotype of variant j as 
the explanatory variable:
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(4)
Pr(Aj|D) in Equation (2) is then a function of the χj2:
(5)
where l0 = Pr (D|A0, β0̂). We make the assumption that the prior causal probability for all 
variants is equal, i.e., Pr(Aj) is the same across all variants j. Equation (5) can then be 
simplified with a constant for the term  and the probability that variant j 
is causal can be calculated using
(6)
which can be normalized across all variants as
(7)
Finally, the 99% credible set of variants is defined as the smallest set of models, with each 
model designating one causal variant, S = {Aj}, such that
(8)
This credible set of variants has 99% probability of containing the causal variant, given the 
assumption that there is a true association and that all possible causal variants have been 
genotyped (both assumptions are likely to be valid in genome-wide significant regions of 
data that have been imputed to 1000 Genomes). We have made the R-script for 
implementing the method freely available online (URLs).
eQTL credible set overlap analysis
To assess if the association statistics in the 38 migraine loci could be explained by credible 
overlapping eQTL signals, we used two eQTL microarray datasets. The first consisted of 
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3,754 samples from peripheral venous blood85 and the second was from a meta-analysis of 
human brain cortex studies of 550 samples86. From both studies we obtained summary 
statistics from an association test of putative cis-eQTLs between all SNP-transcript pairs 
within a 1-Mb window of each other. Then for the most significant eQTLs (P < 1 × 10−4) 
found for genes within a 1Mb window of migraine credible set variants (see Defining 
credible sets), we created an additional credible set of markers for each eQTL. We then 
tested (using Spearman’s rank correlation) whether there was a significant correlation 
between the association test-statistics in each migraine credible set compared to the 
expression test-statistics in each overlapping eQTL credible set. Significant correlation 
between a migraine credible set and an eQTL credible set was taken as evidence of the 
migraine locus tagging a real eQTL. An appropriate significance threshold for multiple 
testing was determined by Bonferroni correction.
GTEx tissue enrichment analysis
Gene sets for each locus were obtained by taking all genes within 50kb of credible set SNPs. 
Identified genes were then analyzed for tissue enrichment using publicly available 
expression data from the pilot phase of the Genotype-Tissue Expression project (GTEx)62, 
version 3. In this dataset, postmortem samples from 42 human tissues and three cell lines 
across 1,641 samples (Supplementary Table 16) were used for bulk RNA sequencing 
according to a unified protocol. All samples were sequenced using Illumina 76 base-pair 
paired-end reads. Collapsed reads per kilobase per million mapped reads (RPKM) values for 
52,577 transcripts were filtered for those with unique HGNC IDs (n = 20,932). We also 
excluded transcripts from any non-coding RNAs. All transcripts were ranked by mean 
RPKM across all samples and 100,000 permutations of each credible set gene list were 
generated by selecting a random transcript for each entry in the credible set within +/−100 
ranks of the transcript for that gene. For each sample, the RPKM values were converted into 
ranks for that transcript, and sums of ranks within each tissue were computed for each gene. 
Enrichment P-values for each tissue were calculated by taking the total number of instances 
where the gene list of interest had a lower sum of ranks than the permuted sum of ranks 
(divided by the total number of permutations). We estimated the number of independent 
tissues via the matSpD tool87 and then used Bonferroni correction to adjust for 27 
independent tests (P < 1.90 × 10−3).
Specificity of individual genes in GTEx tissues
We selected the nearest gene to the index SNP at each migraine locus and then investigated 
the individual expression activity of each of these genes. As the number of samples for some 
tissues was small, we grouped individual tissues into four categories; brain, vascular, 
gastrointestinal, and other tissues (Supplementary Table 16). For each selected gene, we then 
tested whether the average expression (mean RPKM) was significantly higher in a particular 
tissue group compared to the ‘other tissues’ category. We assessed significance using a one-
tailed t-test and used Bonferroni correction to adjust for 114 tests (38 genes × 3 tissue 
groups). While some genes were observed to be significantly expressed in multiple tissue 
groups, we determined that a gene was tissue-specific if it was only expressed highly in one 
tissue group (i.e. brain, vascular, or gastrointestinal, Supplementary Table 25).
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eQTL credible set analysis in GTEx tissues
For all tissues and transcripts (filtered as above), we identified genome-wide significant (P < 
2 × 10−13) cis-eQTLs within a 1Mb window of each transcript and created credible sets (see 
Defining credible sets) for each eQTL locus identified in each tissue. We found a total of 35 
of these significant eQTL credible sets within a 1Mb window of the migraine loci, however, 
only seven out of 35 contained variants that overlapped with a migraine credible set. For 
these seven eQTL credible sets, we then tested (Spearman’s rank correlation) if the test 
statistics between the two overlapping credible sets were significantly correlated. Significant 
correlation between a migraine credible set and an eQTL credible set was taken as evidence 
of the migraine locus tagging a real eQTL. Multiple testing was controlled for using 
Bonferroni correction (i.e. for seven tests at P < 7.1 × 10−3).
Enhancer enrichment analysis
Markers of gene regulation were defined using ChIP-seq datasets from ENCODE66 and the 
NIH Roadmap Epigenome65 projects. Based on the histone H3K27ac signal, which 
identifies active enhancers, we processed data from 56 cell lines and tissue samples to 
identify cell/tissue-specific enhancers, which we define as the 10% of enhancers with the 
highest ratio of reads in that cell/tissue type divided by the total reads88. The raw data is 
publicly available (URLs) and a description of the 56 tissues/cell types is provided in 
Supplementary Table 21. We mapped the credible set variants at each migraine locus to 
these enhancer sites and compared the overlap observed with tissue-specific enhancers 
relative to a background of 10,000 randomly selected sets of SNPs of equal size. We 
restricted the background selection to 1000 Genomes project variants (MAF > 1%) that also 
passed QC filters in the meta-analysis (i.e. to only allow the selection of SNPs that had an a 
priori chance of being associated). The selection procedure then involved randomly selecting 
genomic regions that were of equivalent length and density of enhancers as found in the 
original locus. Once an appropriate region was found, a set of SNPs was randomly selected 
to match the number of SNPs in the credible set for that locus. If the selected SNPs mapped 
to an equal number of enhancer sites (of any tissue type) as credible SNPs from the original 
locus, then these were added to the background set of SNPs for comparison. If the selected 
SNPs did not map to the correct number of enhancers, the selection procedure was repeated 
until an appropriate set was found. This procedure was repeated 10,000 times for each locus 
to obtain an empirical null distribution. The enrichment significance was then estimated 
empirically by calculating the proportion of replicates that were greater than the observed 
value. Finally, we used Bonferroni correction to adjust for multiple testing of 56 tissue/cell 
types (P < 8.9 × 10−4).
Gene Ontology enrichment analysis
The set of 38 genes that are nearest to the index SNP in each migraine locus was chosen and 
tested for over-representation in Gene Ontology (GO) annotations. The PANTHER89 tool 
(URLs) was used to perform the analysis implementing a binomial test to determine if the 
number of genes from the migraine test set found in each GO Pathway is likely to have 
occurred by chance alone. The association P-values were adjusted for the number of 
pathways tested by Bonferroni correction.
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DEPICT reconstituted gene set enrichment analysis
DEPICT63 (Data-driven Expression Prioritized Integration for Complex Traits) is a 
computational tool, which, given a set of GWA study summary statistics, allows 
prioritization of genes in associated loci, enrichment analysis of reconstituted gene sets, and 
tissue enrichment analysis. DEPICT was run using 124 independent genome-wide 
significant SNPs as input (PLINK clumping parameters: --clump-p1 5e-8 --clump-p2 1e-5 --
clump-r2 0.6 --clump-kb 250. Note, rs12845494 and rs140002913 could not be mapped). 
LD distance (r2 > 0.5) was used to define locus boundaries (note that this locus definition is 
different than used elsewhere in the text) yielding 37 autosomal loci comprising 78 genes. 
DEPICT was run using default settings, that is, 500 permutations for bias adjustment, 20 
replications for false discovery rate estimation, normalized expression data from 77,840 
Affymetrix microarrays for gene set reconstitution (see reference90), 14,461 reconstituted 
gene sets for gene set enrichment analysis, and testing 209 tissue/cell types assembled from 
37,427 Affymetrix U133 Plus 2.0 Array samples for enrichment in tissue/cell type 
expression.
Post-analysis, we omitted reconstituted gene sets in which genes in the original gene set 
were not nominally enriched (Wilcoxon rank-sum test) because, by design, genes in the 
original gene set are expected to be enriched in the reconstituted gene set. Therefore, lack of 
enrichment complicates interpretation because the label of the reconstituted gene set may be 
inaccurate. Hence, the eight reconstituted gene sets were removed from the results: MP:
0002089, MP:0002190, ENSG00000151577, ENSG00000168615, ENSG00000143322, 
ENSG00000112531, ENSG00000161021, and ENSG00000100320. We also removed an 
association identified for another gene set (ENSG00000056345 PPI, P = 1.7×10−4, FDR = 
0.04) because it is no longer part of the Ensembl database. The Affinity Propagation tool91 
was finally used to cluster related reconstituted gene sets into 10 groups (URLs).
DEPICT tissue enrichment analysis
DEPICT used data from 37,427 human microarray samples captured on the Affymetrix 
HGU133a2.0 platform to test if genes in the 38 migraine loci are highly expressed in 209 
tissues/cell types with Medical Subject Heading (MeSH) annotations. The annotation 
procedure and method for normalizing expression profiles across annotations is outlined in 
the original publication63. The tissue/cell type enrichment analysis algorithm was 
conceptually identical to the gene set enrichment analysis whereby enrichment P-values 
were calculated empirically using 500 permutations for bias adjustment and 20 replications 
for false discovery rate estimation.
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Figure 1. 
Manhattan plot of the primary meta-analysis of all migraine (59,674 cases vs. 316,078 
controls). Each marker was tested for association using an additive genetic model by logistic 
regression adjusted for sex. A fixed-effects meta-analysis was then used to combine the 
association statistics from all 22 clinic and population-based studies. The horizontal axis 
shows the chromosomal position and the vertical axis shows the significance of tested 
markers from logistic regression. Markers that reach genome-wide significance (P < 5 × 
10−8) at previously known and newly identified loci are highlighted according to the color 
legend.
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Figure 2. 
Gene expression enrichment of genes from the migraine loci in GTEx tissues. Expression 
data from 1,641 samples was obtained using RNAseq for 42 tissues and three cell lines from 
the GTEx consortium. Enrichment P-values were assessed empirically for each tissue using 
a permutation procedure (100,000 replicates) and the red vertical line shows the significance 
threshold after adjusting for multiple testing by Bonferroni correction (see Online 
Methods).
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Figure 3. 
Gene expression enrichment of genes from the migraine loci in 209 tissue/cell type 
annotations by DEPICT. Expression data was obtained from 37,427 human microarray 
samples and then genes in the migraine loci were assessed for high expression in each of the 
annotation categories. Enrichment P-values were determined by comparing the expression 
pattern from the migraine loci to 500 randomly generated loci and the false discovery rate 
(horizontal dashed line) was estimated to control for multiple testing (see Online Methods). 
A full list of these enrichment results are provided in Supplementary Table 20.
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Figure 4. 
Enrichment of the migraine loci in sets of tissue-specific enhancers. We mapped credible 
sets from the migraine loci to sets of enhancers under active expression in 56 tissues and cell 
lines (identified by H3K27ac histone marks from the Roadmap Epigenomics65 and 
ENCODE66 projects). Enrichment P-values were assessed empirically by randomly 
generating a background set of matched loci for comparison (10,000 replicates) and the 
vertical dotted line is the significance threshold after adjusting for 56 separate tests by 
Bonferroni correction (see Online Methods).
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Figure 5. 
DEPICT network of the reconstituted gene sets that were significantly enriched (false 
discovery rate < 0.05) for genes at the migraine loci (Online Methods). Enriched gene sets 
are represented as nodes with pairwise overlap denoted by the width of the connecting lines 
and empirical enrichment P-value is indicated by color intensity (darker is more significant). 
The 67 significantly enriched gene sets were clustered by similarity into 10 group nodes as 
shown in (a) where each group node is named after the most representative gene set in the 
group. (b) Shows one example of gene sets that were clustered within the now expanded 
ITGB1 PPI group. A full list of the 67 significantly enriched reconstituted gene sets can be 
found in Supplementary Table 23.
Gormley et al. Page 28
Nat Genet. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gormley et al. Page 29
Ta
bl
e 
1
In
di
v
id
ua
l I
H
G
C 
G
W
A
 st
ud
ie
s l
ist
ed
 w
ith
 c
as
es
 a
nd
 c
on
tro
l n
um
be
rs
 u
se
d 
in
 th
e 
pr
im
ar
y 
an
al
ys
is 
(al
l m
igr
ain
e) 
an
d i
n t
he
 su
bty
pe
 an
aly
ses
 (m
igr
ain
e 
w
ith
 a
ur
a 
an
d 
m
ig
ra
in
e 
w
ith
ou
t a
ur
a).
 N
ote
 th
at 
ch
rom
os
om
e X
 ge
no
typ
e d
ata
 w
as
 u
n
av
ai
la
bl
e 
fro
m
 th
re
e 
of
 th
e 
in
di
v
id
ua
l G
W
A
 st
ud
ie
s (
EG
CU
T, 
R
ot
te
rd
am
 II
I, 
an
d 
Tw
in
sU
K
) a
nd
 al
so
 pa
rti
all
y u
na
v
ai
la
bl
e 
fro
m
 so
m
e 
of
 th
e 
co
nt
ro
l s
am
pl
es
 (s
pe
cif
ic
al
ly
 th
e 
G
SK
 c
on
tro
ls)
 us
ed
 fo
r t
he
 ‘G
erm
an
 M
O’
 
st
ud
y, 
m
ea
n
in
g 
th
at
 th
e 
nu
m
be
r o
f s
am
pl
es
 a
na
ly
ze
d 
on
 c
hr
om
os
om
e 
X
 w
as
 5
7,
75
6 
ca
se
s a
nd
 2
99
,1
09
 co
nt
ro
ls.
 C
om
pl
et
e d
at
a w
as
 a
v
ai
la
bl
e 
on
 th
e 
au
to
so
m
es
 fo
r a
ll 
sa
m
pl
es
.
G
W
A
 S
tu
dy
 ID
Fu
ll 
N
am
e o
f G
W
A
 S
tu
dy
A
ll 
m
ig
ra
in
e
M
ig
ra
in
e 
w
ith
 a
ur
a
M
ig
ra
in
e 
w
ith
ou
t a
ur
a
C
as
es
C
on
tr
o
ls
C
as
es
C
on
tr
o
ls
C
as
es
C
on
tr
o
ls
23
an
dM
e
23
an
dM
e 
In
c.
30
,4
65
14
3,
14
7
-
-
-
-
A
LS
PA
C
Av
o
n
 L
on
gi
tu
di
na
l S
tu
dy
 o
f P
ar
en
ts
 a
nd
 C
hi
ld
re
n
3,
13
4
5,
10
3
-
-
-
-
AT
M
A
us
tra
lia
n 
Tw
in
 M
ig
ra
in
e
1,
68
3
2,
38
3
-
-
-
-
B
58
C
19
58
 B
rit
ish
 B
irt
h 
Co
ho
rt
1,
16
5
4,
14
1
-
-
-
-
D
an
ish
 H
C
D
an
ish
 H
ea
da
ch
e 
Ce
nt
er
1,
77
1
1,
00
0
77
5
1,
00
0
99
6
1,
00
0
D
eC
O
D
E
de
CO
D
E 
G
en
et
ic
s I
nc
.
3,
13
5
95
,5
85
36
6
95
,5
85
60
8
95
,5
85
D
ut
ch
 M
A
D
ut
ch
 m
ig
ra
in
e 
w
ith
 a
ur
a
73
4
5,
21
1
73
4
5,
21
1
-
-
D
ut
ch
 M
O
D
ut
ch
 m
ig
ra
in
e 
w
ith
ou
t a
ur
a
1,
11
5
2,
02
8
-
-
1,
11
5
2,
02
8
EG
CU
T
Es
to
ni
an
 G
en
om
e 
Ce
nt
er
,
 
U
ni
v
er
sit
y 
of
 T
ar
tu
81
3
9,
85
0
76
9,
85
0
94
9,
85
0
Fi
nn
ish
 M
A
Fi
nn
ish
 m
ig
ra
in
e 
w
ith
 a
ur
a
93
3
2,
71
5
93
3
2,
71
5
-
-
G
er
m
an
 M
A
G
er
m
an
 m
ig
ra
in
e 
w
ith
 a
ur
a
1,
07
1
1,
01
0
1,
07
1
1,
01
0
-
-
G
er
m
an
 M
O
G
er
m
an
 m
ig
ra
in
e 
w
ith
ou
t a
ur
a
1,
16
0
1,
64
7
-
-
1,
16
0
1,
64
7
H
U
N
T
N
or
d-
Tr
øn
de
la
g 
H
ea
lth
 S
tu
dy
1,
39
5
1,
01
1
29
0
1,
01
1
98
0
1,
01
1
N
FB
C
N
or
th
er
n 
Fi
nn
ish
 B
irt
h 
Co
ho
rt
75
6
4,
39
3
-
-
-
-
N
TR
/N
ES
DA
N
et
he
rla
nd
s T
w
in
 R
eg
ist
er
 a
nd
 th
e 
N
et
he
rla
nd
s
St
ud
y 
of
 D
ep
re
ss
io
n 
an
d 
A
nx
ie
ty
1,
63
6
3,
81
9
54
4
3,
81
9
61
5
3,
81
9
R
ot
te
rd
am
 II
I
R
ot
te
rd
am
 S
tu
dy
 II
I
48
7
2,
17
5
10
6
2,
17
5
38
1
2,
17
5
Sw
ed
ish
 T
w
in
s
Sw
ed
ish
 T
w
in
 R
eg
ist
ry
1,
30
7
4,
18
2
-
-
-
-
Tr
o
m
sø
Th
e 
Tr
o
m
sø
 S
tu
dy
66
0
2,
40
7
-
-
-
-
Tw
in
s U
K
Tw
in
s U
K
61
8
2,
33
4
20
2
2,
33
4
41
6
2,
33
4
W
G
H
S
W
o
m
en
’s
 G
en
om
e 
H
ea
lth
 S
tu
dy
5,
12
2
18
,1
08
1,
17
7
18
,1
08
1,
82
6
18
,1
08
Yo
u
n
g 
Fi
nn
s
Yo
u
n
g 
Fi
nn
s
37
8
2,
06
5
58
2,
06
5
15
7
2,
06
5
Nat Genet. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gormley et al. Page 30
G
W
A
 S
tu
dy
 ID
Fu
ll 
N
am
e 
of
 G
W
A
 S
tu
dy
A
ll 
m
ig
ra
in
e
M
ig
ra
in
e 
w
ith
 a
ur
a
M
ig
ra
in
e 
w
ith
ou
t a
ur
a
C
as
es
C
on
tr
o
ls
C
as
es
C
on
tr
o
ls
C
as
es
C
on
tr
o
ls
To
ta
l:
59
,6
74
31
6,
07
8
6,
33
2
14
4,
88
3
8,
34
8
13
9,
62
2
Nat Genet. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gormley et al. Page 31
Ta
bl
e 
2
Su
m
m
ar
y 
of
 th
e 
38
 g
en
om
ic
 lo
ci
 a
ss
oc
ia
te
d 
w
ith
 th
e 
pr
ev
al
en
t t
yp
es
 o
f m
ig
ra
in
e.
 T
en
 lo
ci
 w
er
e 
pr
ev
io
us
ly
 re
po
rte
d 
(P
ub
M
ed
 ID
s l
ist
ed
) a
nd
 28
 ar
e n
ew
ly
 
fo
un
d 
in
 th
is 
stu
dy
.
 
Ea
ch
 lo
cu
s i
s l
ab
el
ed
 w
ith
 p
ro
te
in
 c
od
in
g 
ge
ne
s t
ha
t o
v
er
la
p 
th
e 
re
gi
on
. I
nt
er
ge
ni
c 
lo
ci
 a
re
 a
lso
 la
be
le
d 
w
ith
 th
e 
pr
ef
ix
 “
ne
ar
” 
to
 
hi
gh
lig
ht
 th
e 
ad
di
tio
na
l u
nc
er
ta
in
ty
 in
 id
en
tif
yi
ng
 re
le
v
an
t g
en
es
. E
ffe
ct
 si
ze
s a
nd
 P
-
v
al
ue
s f
or
 e
ac
h 
SN
P 
w
er
e 
ca
lc
ul
at
ed
 fo
r e
ac
h 
stu
dy
 w
ith
 a
n 
ad
di
tiv
e 
ge
ne
tic
 m
od
el
 u
sin
g 
lo
gi
sti
c 
re
gr
es
sio
n 
ad
jus
ted
 fo
r s
ex
 a
n
d 
th
en
 c
om
bi
ne
d 
in
 a
 fi
xe
d-
ef
fe
ct
s m
et
a-
an
al
ys
is.
 F
o
r 
lo
ci
 th
at
 c
on
ta
in
 a
 se
co
nd
ar
y 
LD
-
in
de
pe
nd
en
t s
ig
na
l p
as
sin
g 
ge
no
m
e-
w
id
e 
sig
ni
fic
an
ce
, t
he
 se
co
nd
ar
y 
in
de
x
 S
N
P 
an
d 
P-
v
al
ue
 is
 g
iv
en
. 
Fo
r 
th
e 
se
v
en
 lo
ci
 re
ac
hi
ng
 g
en
om
e-
w
id
e 
sig
ni
fic
an
ce
 in
 th
e 
m
ig
ra
in
e 
w
ith
ou
t a
ur
a 
su
b-
ty
pe
 a
na
ly
sis
, t
he
 c
or
re
sp
on
di
ng
 in
de
x
 S
N
P 
an
d 
P-
v
al
ue
 a
re
 a
lso
 g
iv
en
. 
Ev
id
en
ce
 fo
r s
ig
ni
fic
an
t 
he
te
ro
ge
ne
ity
 w
as
 fo
un
d 
at
 fo
ur
 lo
ci
 (T
RP
M
8/
HJ
UR
P,
 
M
RV
I1
,
 
n
ea
r 
ZC
CH
C1
4,
 
an
d 
ne
ar
 C
CM
2L
/H
CK
) s
o f
or 
tho
se 
we
 pr
ese
nt 
the
 re
su
lts
 of
 a 
ran
do
m-
ef
fe
ct
s m
od
el
.
Lo
cu
s
R
an
k
Lo
cu
s
C
hr
In
de
x 
SN
P
M
in
or
A
lle
le
M
A
F
A
ll 
M
ig
ra
in
e
Se
co
nd
ar
y 
sig
na
l
M
ig
ra
in
e 
w
ith
ou
t a
ur
a
Pr
ev
io
us
Pu
bl
ic
at
io
n
PM
ID
O
R
 [9
5%
 C
I]
P
In
de
x 
SN
P
P
In
de
x 
SN
P
P
1
LR
P1
/S
TA
T6
/S
DR
9C
7
12
rs
11
17
21
13
C
0.
42
0.
90
 [0
.89
–0
.91
]
5.
6 
× 
10
−
49
rs
11
17
20
55
1.
3 
× 
10
−
09
rs
11
17
21
13
4.
3 
× 
10
−
16
21
66
66
92
2
PR
D
M
16
1
rs
10
21
84
52
G
0.
22
1.
11
 [1
.10
–1
.13
]
5.
3 
× 
10
−
38
rs
12
13
50
62
3.
7 
× 
10
−
10
-
-
21
66
66
92
3
FH
L5
/U
FL
1
6
rs
67
33
82
27
T
0.
23
1.
09
 [1
.08
–1
.11
]
2.
0 
× 
10
−
27
rs
48
39
82
7
5.
7 
× 
10
−
10
rs
77
75
72
1
1.
1 
× 
10
−
12
23
79
30
25
4
n
ea
r 
TS
PA
N
2/
NG
F
1
rs
20
78
37
1
C
0.
12
1.
11
 [1
.09
–1
.13
]
4.
1 
× 
10
−
24
rs
75
44
25
6
8.
7 
× 
10
−
09
rs
20
78
37
1
7.
4 
× 
10
−
09
23
79
30
25
5
TR
PM
8/
HJ
UR
P
2
rs
10
16
69
42
C
0.
20
0.
94
 [0
.89
–0
.99
]
1.
0 
× 
10
−
23
rs
56
65
29
2.
5 
× 
10
−
09
rs
67
24
62
4
1.
1 
× 
10
−
09
21
66
66
92
6
PH
AC
TR
1
6
rs
93
49
37
9
G
0.
41
0.
93
 [0
.92
–0
.95
]
5.
8 
× 
10
−
22
-
-
rs
93
49
37
9
2.
1 
× 
10
−
09
22
68
37
12
7
M
EF
2D
1
rs
19
25
95
0
G
0.
35
1.
07
 [1
.06
–1
.09
]
9.
1 
× 
10
−
22
-
-
-
-
22
68
37
12
8
SL
C2
4A
3
20
rs
48
14
86
4
C
0.
26
1.
07
 [1
.06
–1
.09
]
2.
2 
× 
10
−
19
-
-
-
-
-
9
n
ea
r 
FG
F6
12
rs
10
24
90
5
G
0.
47
1.
06
 [1
.04
–1
.08
]
2.
1 
× 
10
−
17
-
-
rs
10
24
90
5
2.
5 
× 
10
−
09
-
10
C7
or
f1
0
7
rs
18
61
66
89
1
T
0.
11
1.
09
 [1
.07
–1
.12
]
9.
7 
× 
10
−
16
-
-
-
-
23
79
30
25
11
PL
CE
1
10
rs
10
78
61
56
G
0.
45
0.
95
 [0
.94
–0
.96
]
2.
0 
× 
10
−
14
rs
75
47
36
20
5.
8 
× 
10
−
09
-
-
-
12
K
CN
K5
6
rs
10
45
61
00
T
0.
28
1.
06
 [1
.04
–1
.07
]
6.
9 
× 
10
−
13
-
-
-
-
-
13
A
ST
N2
9
rs
64
78
24
1
A
0.
36
1.
05
 [1
.04
–1
.07
]
1.
2 
× 
10
−
12
-
-
rs
64
78
24
1
1.
2 
× 
10
−
10
22
68
37
12
14
M
RV
I1
11
rs
49
10
16
5
C
0.
33
0.
94
 [0
.91
–0
.98
]
2.
9 
× 
10
−
11
-
-
-
-
-
15
H
PS
E2
10
rs
12
26
01
59
A
0.
07
0.
92
 [0
.89
–0
.94
]
3.
2 
× 
10
−
10
-
-
-
-
-
16
CF
DP
1
16
rs
77
50
59
15
T
0.
45
1.
05
 [1
.03
–1
.06
]
3.
3 
× 
10
−
10
-
-
-
-
-
17
RN
F2
13
17
rs
17
85
71
35
C
0.
17
1.
06
 [1
.04
–1
.08
]
5.
2 
× 
10
−
10
-
-
-
-
-
18
N
RP
1
10
rs
25
06
14
2
G
0.
17
1.
06
 [1
.04
–1
.07
]
1.
5 
× 
10
−
09
-
-
-
-
-
19
n
ea
r 
GP
R1
49
3
rs
13
07
89
67
C
0.
03
0.
87
 [0
.83
–0
.91
]
1.
8 
× 
10
−
09
-
-
-
-
-
Nat Genet. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gormley et al. Page 32
Lo
cu
s
R
an
k
Lo
cu
s
C
hr
In
de
x 
SN
P
M
in
or
A
lle
le
M
A
F
A
ll 
M
ig
ra
in
e
Se
co
nd
ar
y 
sig
na
l
M
ig
ra
in
e 
w
ith
ou
t a
ur
a
Pr
ev
io
us
Pu
bl
ic
at
io
n
PM
ID
O
R
 [9
5%
 C
I]
P
In
de
x 
SN
P
P
In
de
x 
SN
P
P
20
n
ea
r 
JA
G1
20
rs
11
14
04
21
8
G
0.
34
1.
05
 [1
.03
–1
.07
]
2.
0 
× 
10
−
09
-
-
-
-
-
21
n
ea
r 
RE
ST
/S
PI
NK
2
4
rs
76
84
25
3
C
0.
45
0.
96
 [0
.94
–0
.97
]
2.
5 
× 
10
−
09
-
-
-
-
-
22
n
ea
r 
ZC
CH
C1
4
16
rs
40
81
94
7
G
0.
34
1.
03
 [1
.00
–1
.06
]
2.
5 
× 
10
−
09
-
-
-
-
-
23
H
EY
2/
NC
OA
7
6
rs
12
68
08
3
C
0.
48
0.
96
 [0
.95
–0
.97
]
5.
3 
× 
10
−
09
-
-
-
-
-
24
n
ea
r 
W
SC
D1
/N
LR
P1
17
rs
75
21
30
74
T
0.
03
0.
89
 [0
.86
–0
.93
]
7.
1 
× 
10
−
09
-
-
-
-
-
25
n
ea
r 
GJ
A
1
6
rs
28
45
57
31
T
0.
16
1.
06
 [1
.04
–1
.08
]
7.
3 
× 
10
−
09
-
-
-
-
-
26
n
ea
r 
TG
FB
R2
3
rs
67
91
48
0
T
0.
31
1.
04
 [1
.03
–1
.06
]
7.
8 
× 
10
−
09
-
-
-
-
22
68
37
12
27
n
ea
r 
IT
PK
1
14
rs
11
62
47
76
C
0.
31
0.
96
 [0
.94
–0
.97
]
7.
9 
× 
10
−
09
-
-
-
-
-
28
n
ea
r 
A
DA
M
TS
L4
/E
CM
1
1
rs
66
93
56
7
C
0.
27
1.
05
 [1
.03
–1
.06
]
1.
2 
× 
10
−
08
-
-
-
-
-
29
n
ea
r 
CC
M
2L
/H
CK
20
rs
14
40
17
10
3
T
0.
02
0.
85
 [0
.76
–0
.96
]
1.
2 
× 
10
−
08
-
-
-
-
-
30
YA
P1
11
rs
10
89
52
75
A
0.
33
1.
04
 [1
.03
–1
.06
]
1.
6 
× 
10
−
08
-
-
-
-
-
31
n
ea
r 
M
ED
14
/U
SP
9X
X
rs
12
84
54
94
G
0.
27
0.
96
 [0
.95
–0
.97
]
1.
7 
× 
10
−
08
-
-
-
-
-
32
n
ea
r 
D
OC
K4
/IM
M
P2
L
7
rs
10
15
58
55
T
0.
05
1.
08
 [1
.05
–1
.12
]
2.
1 
× 
10
−
08
-
-
-
-
-
33
1p
31
.1
*
1
rs
15
72
66
8
G
0.
48
1.
04
 [1
.02
–1
.05
]
2.
1 
× 
10
−
08
-
-
-
-
-
34
CA
RF
2
rs
13
85
56
41
3
T
0.
03
0.
88
 [0
.84
–0
.92
]
2.
3 
× 
10
−
08
-
-
-
-
-
35
A
RM
S2
/H
TR
A1
10
rs
22
23
08
9
C
0.
08
0.
93
 [0
.91
–0
.95
]
3.
0 
× 
10
−
08
-
-
-
-
-
36
IG
SF
9B
11
rs
56
15
61
T
0.
12
0.
94
 [0
.92
–0
.96
]
3.
4 
× 
10
−
08
-
-
-
-
-
37
M
PP
ED
2
11
rs
11
03
11
22
C
0.
24
1.
04
 [1
.03
–1
.06
]
3.
5 
× 
10
−
08
-
-
-
-
-
38
n
ea
r 
N
OT
CH
4
6
rs
14
00
02
91
3
A
0.
06
0.
91
 [0
.88
–0
.94
]
3.
8 
× 
10
−
08
-
-
-
-
-
*
Th
e 
ne
ar
es
t c
od
in
g 
ge
ne
 (L
RR
IQ
3) 
to 
thi
s l
oc
us
 is
 59
2k
b a
w
ay
.
Nat Genet. Author manuscript; available in PMC 2017 March 01.
